Geron Corporation (GERN)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies.
It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
The company was incorporated in 1990 and is headquartered in Foster City, California.
|IPO Date||Jun 30, 1996|
919 East Hillsdale Boulevard
Foster City, California 94404
|Phone||650 473 7700|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. John A. Scarlett||Chief Executive Officer, President and Chairman|
|Olivia Kyusuk Bloom||Executive Vice President of Finance, Chief Financial Officer and Treasurer|
|Dr. Andrew J. Grethlein||Executive Vice President and Chief Operating Officer|
|Melissa A. Kelly Behrs||Executive Vice President and Chief Business Officer|
|Dr. Aleksandra Rizo M.D., Ph.D.||Executive Vice President and Chief Medical Officer|
|Suzanne Messere||Head of Investor Relations and Corporate Communications|
|Stephen N. Rosenfield||Executive Vice President, Chief Legal Officer and Corporate Secretary|
|Shannon Odam||Vice President of Human Resources|
|Anil Kapur||Chief Commercial Officer and Executive Vice President of Corporate Strategy|